Listen
MABTHERA
-
Opinions on drugs -
Posted on
Nov 08 2006
- Updated on
Jun 09 2009
Reason for request
Inclusion on the list of medicines approved for use by hospitals in the extension of indication: MabThera® maintenance therapy is indicated for patients with relapsed or refractory follicular lymphoma responding to induction therapy with chemotherapy with or without MabThera®.
-
Clinical Benefit
| Substantial |
The actual benefit of MabThera® in the context of maintenance treatment for non-Hodgkin’s follicular lymphoma is substantial. |
Clinical Added Value
| major |
In maintenance treatment for relapsed or refractory follicular lymphoma, MabThera® provides a major IAB (IAB I) in terms of efficacy compared with the current treatment strategy. |
Contact Us
Évaluation des médicaments
